NCT03844256
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT03844256
Title A Study of Mitomycin-c/ Capecitabine ChemoRadiotherapy Combined With Nivolumab Monotherapy or Ipilumimab and Nivolumab, as Bladder Sparing Curative Treatment for Muscle Invasive Bladder Cancer: the CRIMI Study (CRIMI)
Acronym CRIMI
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Indications
Therapies
Age Groups: senior | adult
Covered Countries NLD

Facility Status City State Zip Country Details
Amsterdam UMC, VUmc RECRUITING Amsterdam North Holland 1081 HV Netherlands Details
Amsterdam UMC, AMC RECRUITING Amsterdam North Holland 1105 AZ Netherlands Details
LUMC RECRUITING Leiden South Holland Netherlands Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field